The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD

BACKGROUND: In 2016, the Food and Drug Administration (FDA) changed labeling regarding metformin contraindications in patients with diabetes and CKD from using serum creatinine–based thresholds to using eGFR-based thresholds. Because race and sex affect serum creatinine levels independently of GFR,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Am Soc Nephrol
Autori principali: Shin, Jung-Im, Sang, Yingying, Chang, Alex R., Dunning, Stephan C., Coresh, Josef, Inker, Lesley A., Selvin, Elizabeth, Ballew, Shoshana H., Grams, Morgan E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Nephrology 2020
Soggetti:
Clinical Epidemiology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7460896/
https://ncbi.nlm.nih.gov/pubmed/32660971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019101119
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi